CTBS

Summary

CTBS (chitobiase, HGNC:2496) is a protein-coding gene on chromosome 1p22.3, encoding Di-N-acetylchitobiase (Q01459). Reducing-end exoglycosidase involved in glycan degradation.

Chitobiase is a lysosomal glycosidase involved in degradation of asparagine-linked oligosaccharides on glycoproteins (Aronson and Kuranda, 1989 [PubMed 2531691]).

Source: NCBI Gene 1486 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 72 total
• MANE Select transcript: NM_004388

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2496
Approved symbol	CTBS
Name	chitobiase
Location	1p22.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000117151
Ensembl biotype	protein_coding
OMIM	600873
Entrez	1486

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000370625, ENST00000370630, ENST00000465118, ENST00000477677, ENST00000863691, ENST00000863692, ENST00000863693, ENST00000863694, ENST00000957715

RefSeq mRNA: 1 — MANE Select: NM_004388 NM_004388

CCDS: CCDS698

Canonical transcript exons

ENST00000370630 — 7 exons

Exon	Start	End
ENSE00001823837	84549611	84555199
ENSE00001912166	84574239	84574440
ENSE00003459781	84570582	84570720
ENSE00003464156	84565841	84566012
ENSE00003542715	84563735	84563832
ENSE00003630858	84569931	84570139
ENSE00003657005	84563257	84563418

Expression profiles

Bgee: expression breadth ubiquitous, 247 present calls, max score 93.88.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 46.3997 / max 1445.2533, expressed in 1826 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12988	46.3997	1826

Top tissues by expression

269 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
choroid plexus epithelium	UBERON:0003911	93.88	gold quality
monocyte	CL:0000576	92.63	gold quality
mononuclear cell	CL:0000842	92.28	gold quality
leukocyte	CL:0000738	92.11	gold quality
pigmented layer of retina	UBERON:0001782	91.13	gold quality
blood	UBERON:0000178	90.80	gold quality
islet of Langerhans	UBERON:0000006	90.10	gold quality
stromal cell of endometrium	CL:0002255	88.85	gold quality
right lobe of liver	UBERON:0001114	88.59	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	88.58	gold quality
descending thoracic aorta	UBERON:0002345	87.67	gold quality
ascending aorta	UBERON:0001496	87.43	gold quality
thoracic aorta	UBERON:0001515	87.43	gold quality
gall bladder	UBERON:0002110	87.10	gold quality
rectum	UBERON:0001052	87.07	gold quality
pancreas	UBERON:0001264	86.86	gold quality
right coronary artery	UBERON:0001625	86.85	gold quality
corpus epididymis	UBERON:0004359	86.23	gold quality
body of pancreas	UBERON:0001150	86.12	gold quality
liver	UBERON:0002107	86.08	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.72	gold quality
aorta	UBERON:0000947	85.53	gold quality
right adrenal gland cortex	UBERON:0035827	85.24	gold quality
left adrenal gland	UBERON:0001234	85.14	gold quality
left coronary artery	UBERON:0001626	85.00	gold quality
granulocyte	CL:0000094	84.97	gold quality
right adrenal gland	UBERON:0001233	84.86	gold quality
nasal cavity mucosa	UBERON:0001826	84.80	gold quality
minor salivary gland	UBERON:0001830	84.77	gold quality
epithelial cell of pancreas	CL:0000083	84.58	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.59

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

129 targeting CTBS, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3924	100.00	72.09	2394
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345

Literature-anchored findings (GeneRIF, showing 2)

• biochemical behavior of di-N-acetylchitobiase indicates it has three subsites, -2, -1, +1, in which the reducing-end trimer of any sized chitooligosaccharide is bound. The +1 site is specific for an alpha-anomer. (PMID:16794344)
• Data indicate that infliximab changes the concentration of hexosaminidase (N-acetyl-beta-glucosaminidase; HEX) activity depending on the drug dose and time of administration. (PMID:26768631)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ctbs	ENSDARG00000100002
mus_musculus	Ctbs	ENSMUSG00000028189
rattus_norvegicus	Ctbs	ENSRNOG00000015573
drosophila_melanogaster	Cda5	FBGN0051973
caenorhabditis_elegans		WBGENE00010686

Paralogs (6): CHI3L2 (ENSG00000064886), OVGP1 (ENSG00000085465), CHI3L1 (ENSG00000133048), CHIT1 (ENSG00000133063), CHIA (ENSG00000134216), CHID1 (ENSG00000177830)

Protein

Protein identifiers

Di-N-acetylchitobiase — Q01459 (reviewed: Q01459)

All UniProt accessions (2): Q01459, F6X5H7

UniProt curated annotations — full annotation on UniProt →

Function. Reducing-end exoglycosidase involved in glycan degradation. Hydrolyzes N,N’-diacetylchitobiose (GlnNAc2) and higher chitin-oligosaccharides (GlcNAc(n)) to monomeric GlcNAc acting on reducing-end residues. During N-linked glycoprotein degradation, it cleaves single GlcNAc molecules uniquely from the reducing end of N,N’-diacetylchitobiose units linking oligosaccharides to proteins, and therefore it functions after cleavage of the Asn-GlcNAc bond and asparagine removal by glycosylasparaginase.

Subcellular location. Lysosome.

Pathway. Glycan metabolism; N-glycan degradation. Glycan degradation; chitin degradation.

Similarity. Belongs to the glycosyl hydrolase 18 family.

RefSeq proteins (1): NP_004379* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001223	Glyco_hydro18_cat	Domain
IPR001579	Glyco_hydro_18_chit_AS	Active_site
IPR011583	Chitinase_II/V-like_cat	Domain
IPR017853	GH_hydrolase_sf	Homologous_superfamily
IPR029070	Chitinase_insertion_sf	Homologous_superfamily
IPR047898	DIAC_cat	Domain
IPR051887	GH18_Domain-Containing	Family

Pfam: PF00704

Catalyzed reactions (Rhea), 7 shown:

• N,N’-diacetylchitobiose + H2O = 2 N-acetyl-D-glucosamine (RHEA:30671)
• alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc + H2O = alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-D-GlcNAc + N-acetyl-D-glucosamine (RHEA:84983)
• alpha-hexa-N-acetylchitohexaose + H2O = beta-penta-N-acetylchitopentaose + N-acetyl-alpha-D-glucosamine (RHEA:85195)
• alpha-penta-N-acetylchitopentaose + H2O = beta-tetra-N-acetylchitotetraose + N-acetyl-alpha-D-glucosamine (RHEA:85199)
• alpha-tetra-N-acetylchitotetraose + H2O = beta-tri-N-acetylchitotriose + N-acetyl-alpha-D-glucosamine (RHEA:85203)
• alpha-tri-N-acetylchitotriose + H2O = beta-di-N-acetylchitobiose + N-acetyl-alpha-D-glucosamine (RHEA:85207)
• alpha-di-N-acetylchitobiose + H2O = N-acetyl-beta-D-glucosamine + N-acetyl-alpha-D-glucosamine (RHEA:85211)

UniProt features (10 total): glycosylation site 4, sequence variant 2, signal peptide 1, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q01459-F1	91.87	0.88

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 143 (proton donor)

Glycosylation sites (4): 193, 228, 262, 299

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 157 (showing top): GOBP_OLIGOSACCHARIDE_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, GOBP_OLIGOSACCHARIDE_CATABOLIC_PROCESS, GAUSSMANN_MLL_AF4_FUSION_TARGETS_E_UP, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, BROWNE_HCMV_INFECTION_48HR_DN, MARTINEZ_RB1_TARGETS_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_AMINOGLYCAN_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_AMINO_SUGAR_CATABOLIC_PROCESS, GOBP_AMINO_SUGAR_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_CATABOLIC_PROCESS

GO Biological Process (4): chitin catabolic process (GO:0006032), oligosaccharide catabolic process (GO:0009313), carbohydrate catabolic process (GO:0016052), carbohydrate metabolic process (GO:0005975)

GO Molecular Function (5): chitinase activity (GO:0004568), chitin binding (GO:0008061), hydrolase activity, acting on glycosyl bonds (GO:0016798), hydrolase activity, hydrolyzing O-glycosyl compounds (GO:0004553), hydrolase activity (GO:0016787)

GO Cellular Component (2): obsolete extracellular space (GO:0005615), lysosome (GO:0005764)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
aminoglycan catabolic process	1
chitin metabolic process	1
glucosamine-containing compound catabolic process	1
oligosaccharide metabolic process	1
carbohydrate catabolic process	1
carbohydrate metabolic process	1
catabolic process	1
primary metabolic process	1
hydrolase activity, hydrolyzing O-glycosyl compounds	1
carbohydrate derivative binding	1
hydrolase activity	1
hydrolase activity, acting on glycosyl bonds	1
catalytic activity	1
lytic vacuole	1

Protein interactions and networks

STRING

708 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CTBS	GNG5	P30670	968
CTBS	SMIM23	A6NLE4	536
CTBS	MAN2B1	O00754	504
CTBS	PDE12	Q6L8Q7	482
CTBS	OGA	O60502	476
CTBS	MAN2C1	Q9NTJ4	456
CTBS	CRISP1	P54107	446
CTBS	KTN1	Q86UP2	428
CTBS	NAGA	P17050	418
CTBS	MANBA	O00462	401
CTBS	GYG2	O15488	395
CTBS	MAPK6	Q16659	389
CTBS	HSD17B2	P37059	383
CTBS	EHHADH	Q08426	383
CTBS	ARIH1	Q9Y4X5	381

IntAct

36 interactions, top by confidence:

A	B	Type	Score
RELB	NFKBIE	psi-mi:“MI:0914”(association)	0.670
FBXO6	MAN2B1	psi-mi:“MI:0914”(association)	0.640
DEFA1	MANBA	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
MARVELD2	GAP43	psi-mi:“MI:0914”(association)	0.530
CMA1	MANBA	psi-mi:“MI:0914”(association)	0.530
MARVELD2	RAP2A	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
ST7	A2ML1	psi-mi:“MI:0914”(association)	0.350
PTDSS1	IGLL5	psi-mi:“MI:0914”(association)	0.350
PATE1	MANBA	psi-mi:“MI:0914”(association)	0.350
DEFB136	MANBA	psi-mi:“MI:0914”(association)	0.350
IGF2R	MANBA	psi-mi:“MI:0914”(association)	0.350
DEFB135	MANBA	psi-mi:“MI:0914”(association)	0.350
DEFB123	PFDN6	psi-mi:“MI:0914”(association)	0.350
DEFB110	NME2P1	psi-mi:“MI:0914”(association)	0.350
EDN3	POTEF	psi-mi:“MI:0914”(association)	0.350
PCP4	A2ML1	psi-mi:“MI:0914”(association)	0.350
ELSPBP1	QSOX1	psi-mi:“MI:0914”(association)	0.350
PRG2	QSOX1	psi-mi:“MI:0914”(association)	0.350
IDS	RTCA	psi-mi:“MI:0914”(association)	0.350
NXPH3	ACACB	psi-mi:“MI:0914”(association)	0.350
LILRA5	HGS	psi-mi:“MI:0914”(association)	0.350
TMPRSS5	CLGN	psi-mi:“MI:0914”(association)	0.350
TMEM25	CRLF1	psi-mi:“MI:0914”(association)	0.350
NDP	MYCBP2	psi-mi:“MI:0914”(association)	0.350

BioGRID (34): CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-RNA), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS), CTBS (Affinity Capture-MS)

ESM2 similar proteins: O18835, O18998, O42446, O55070, O77588, O77695, O89107, O97524, O97860, P00639, P04066, P08236, P11936, P11937, P12265, P13686, P21704, P22412, P24855, P49183, P49184, P70158, Q01459, Q01460, Q02809, Q13609, Q2QDE6, Q2QDE7, Q2QDE9, Q2QDF0, Q2QDF1, Q4AEE3, Q4FAT7, Q4FZV0, Q5R5N6, Q5R9N3, Q5RFI5, Q63321, Q641Z7, Q6AYS4

Diamond homologs: Q01458, Q01459, Q01460, Q7KWW8, Q8R242, Q8T293, O31682, C0H404

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 48 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Defensins	5	44.1×	6e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

72 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	5
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

819 predictions. Top by Δscore:

Variant	Effect	Δscore
1:84563243:A:AC	donor_gain	1.0000
1:84563244:C:CC	donor_gain	1.0000
1:84563255:A:AC	donor_gain	1.0000
1:84563256:C:CC	donor_gain	1.0000
1:84563414:TGATC:T	acceptor_gain	1.0000
1:84563419:C:A	acceptor_loss	1.0000
1:84563419:C:CC	acceptor_gain	1.0000
1:84563420:T:A	acceptor_loss	1.0000
1:84563729:TCCTA:T	donor_loss	1.0000
1:84563731:CTACC:C	donor_loss	1.0000
1:84563733:A:AT	donor_loss	1.0000
1:84564206:A:C	donor_gain	1.0000
1:84565835:TCTTA:T	donor_loss	1.0000
1:84565836:CTTA:C	donor_loss	1.0000
1:84565837:TTA:T	donor_loss	1.0000
1:84565838:TA:T	donor_loss	1.0000
1:84565839:A:AC	donor_gain	1.0000
1:84565840:C:A	donor_loss	1.0000
1:84565840:C:CC	donor_gain	1.0000
1:84570721:CT:C	acceptor_loss	1.0000
1:84570722:T:C	acceptor_loss	1.0000
1:84555030:T:TA	donor_gain	0.9900
1:84555031:C:A	donor_gain	0.9900
1:84563417:TC:T	acceptor_gain	0.9900
1:84563418:CC:C	acceptor_gain	0.9900
1:84565834:GTCTT:G	donor_loss	0.9900
1:84565839:AC:A	donor_gain	0.9900
1:84565840:CC:C	donor_gain	0.9900
1:84565840:CCA:C	donor_gain	0.9900
1:84565840:CCAG:C	donor_gain	0.9900

AlphaMissense

2517 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:84563773:A:G	W253R	0.993
1:84563773:A:T	W253R	0.993
1:84555152:A:C	S335R	0.990
1:84555152:A:T	S335R	0.990
1:84555154:T:G	S335R	0.990
1:84555097:A:G	W354R	0.989
1:84555097:A:T	W354R	0.989
1:84570039:A:C	N139K	0.989
1:84570039:A:T	N139K	0.989
1:84555140:C:A	K339N	0.986
1:84555140:C:G	K339N	0.986
1:84570614:G:T	A95D	0.985
1:84570709:A:C	F63L	0.985
1:84570709:A:T	F63L	0.985
1:84570711:A:G	F63L	0.985
1:84563766:C:T	G255D	0.984
1:84563368:A:C	S282R	0.983
1:84563368:A:T	S282R	0.983
1:84563370:T:G	S282R	0.983
1:84563750:G:C	C260W	0.982
1:84565865:C:G	A225P	0.982
1:84565917:C:A	M207I	0.980
1:84565917:C:G	M207I	0.980
1:84565917:C:T	M207I	0.980
1:84569977:A:T	V160D	0.980
1:84555095:C:A	W354C	0.979
1:84555095:C:G	W354C	0.979
1:84555032:C:A	W375C	0.977
1:84555032:C:G	W375C	0.977
1:84563409:A:G	C269R	0.977

dbSNP variants (sampled 300 via entrez): RS1000130325 (1:84558552 A>G), RS1000185189 (1:84549896 C>A,T), RS1000251317 (1:84558259 C>G), RS1000278089 (1:84551503 A>C), RS1000289753 (1:84551792 T>C), RS1000336567 (1:84572627 C>G), RS1000396000 (1:84565154 G>A), RS1000515716 (1:84551516 T>G), RS1000726078 (1:84559302 C>A,T), RS1000856700 (1:84564169 T>C,G), RS1001066500 (1:84557501 C>G,T), RS1001087615 (1:84551906 C>G), RS1001146957 (1:84571681 G>A), RS1001370227 (1:84574155 C>A,T), RS1001426224 (1:84553980 T>C)

Disease associations

OMIM: gene MIM:600873 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90006920_2	Herpes simplex virus 2 mgG-1 antibody levels	5.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009350	Anti-herpes simplex virus 2 IgG measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	6
trichostatin A	affects cotreatment, decreases expression, increases expression	3
sodium arsenite	affects expression, increases expression	2
Silicon Dioxide	decreases expression	2
aristolochic acid I	decreases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases methylation	1
glycidyl methacrylate	decreases expression	1
salinomycin	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cobaltous chloride	increases expression	1
butyraldehyde	decreases expression	1
ochratoxin A	increases expression	1
di-n-butylphosphoric acid	affects expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
CC-8490	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases expression	1
NSC 689534	increases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Air Pollutants	decreases expression, increases abundance	1
Atrazine	increases expression	1
Benzo(a)pyrene	increases methylation	1

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery